A short history of biological therapy for psoriatic arthritis

Clinical and Experimental Rheumatology

Volumn 33, Issue , 2015, Pages 104-108

  Mease, Philip ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

IL12 23 inhibition; IL17 inhibition; IL23 inhibition; Psoriasis; Psoriatic arthritis; TNF inhibition

Indexed keywords

ABATACEPT; ADALIMUMAB; B7 ANTIGEN; CD86 ANTIGEN; CERTOLIZUMAB PEGOL; CLAZAKIZUMAB; ETANERCEPT; GOLIMUMAB; GUSELKUMAB; INFLIXIMAB; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 23; IXEKIZUMAB; METHOTREXATE; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE; SECUKINUMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; USTEKINUMAB; ANTIINFLAMMATORY AGENT; AUTACOID; BIOLOGICAL PRODUCT; TUMOR NECROSIS FACTOR;

ANTIBODY RESPONSE; ARTHRITIS; ARTICLE; BIOLOGICAL THERAPY; CYTOKINE RESPONSE; DACTYLITIS; DISEASE ACTIVITY; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; ENTHESITIS; FUNCTIONAL DISEASE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; IMMUNOGENICITY; PREMATURE MORTALITY; PRIORITY JOURNAL; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; PSORIATIC ARTHRITIS; QUALITY OF LIFE; REMISSION; SHORT FORM 36; SPONDYLITIS; T LYMPHOCYTE ACTIVATION; TH1 CELL; UNSPECIFIED SIDE EFFECT; ANIMAL; ANTAGONISTS AND INHIBITORS; ARTHRITIS, PSORIATIC; B LYMPHOCYTE; DRUG EFFECTS; HISTORY; IMMUNOLOGY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ARTHRITIS, PSORIATIC; B-LYMPHOCYTES; BIOLOGICAL PRODUCTS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; INFLAMMATION MEDIATORS; REMISSION INDUCTION; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84958180383     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. MEASE PJ, GLADMAN DD, KEYSTONE EC: Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: Results of a randomized, double-blind, placebocontrolled study. Arthritis Rheum 2006; 54: 1638-45.
2. PAPP K, MEASE P, GAROVOY M et al.: Efalizumab in patients with psoriatic arthritis: results of a phase II randomized double-blind placebo controlled study. J Cutan Med Surg 2006 11: 57-66.
3. MEASE PJ, GOFFE BS, METZ J et al.: Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356: 385-90.
4. CLEGG DO, REDA DJ, MEJIAS E et al.: Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996; 39: 2013-20.
5. MEASE PJ: Psoriatic arthritis: update on pathophysiology, assessment and management. Ann Rheum Dis 2011; 70 (Suppl. 1): i77-84.
6. ANTONI CE, KAVANAUGH A, KIRKHAM B et al.: Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005; 52: 1227-36.
7. MEASE P, KIVITZ A, BURCH F et al.: Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004; 50: 2264-72.
8. ANTONI C, KRUEGER GG, de VLAM K et al.: Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005; 64: 1150-7.
9. MEASE P, GLADMAN D, RITCHLIN C: Adalimumab in the treatment of patients with moderately to severely active psoriatic arthritis: Results of ADEPT. Arthritis Rheum 2005; 58: 3279-89.
10. KAVANAUGH A, MCINNES I, MEASE P et al.: Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009; 60: 976-86.
11. MEASE PJ, FLEISCHMANN R, DEODHAR AA et al.: Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 doubleblind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis 2014; 73: 48-55.
12. MEASE PJ: Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI). Arthritis Care Res (Hoboken) 2011; 63 (Suppl. 11): S64-85.
13. MEASE P: Psoriatic arthritis and spondyloarthritis assessment and management update. Curr Opin Rheumatol 2013; 25: 287-96.
14. MEASE P, COLLIER D, KARKI N et al.: Persistence and predictors of biologic TNFi therapy among biologic naïve psoriatic arthritis patients in a US registry. Arthritis and Rheum 2014; 66 (S10): abs 1853.
15. FAGERLI KM, LIE E, van der HEIJDE D et al.: The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study. Ann Rheum Dis 2014; 73: 132-7.
16. JORGENSEN TS, KRISTENSEN LE, CHRISTENSEN R et al.: Effectiveness and drug adherence of biologic monotherapy in routine care of patients with rheumatoid arthritis: a cohort study of patients registered in the Danish biologics registry. Rheumatology (Oxford) 2015.
17. THOMAS SS, BORAZAN N, BARROSO N et al.: Comparative immunogenicity of TNF inhibitors: impact on clinical efficacy and tolerability in the management of autoimmune diseases. A systematic review and meta-analysis. BioDrugs 2015; 29: 241-58.
18. ZISAPEL M, ZISMAN D, MADAR-BALAKIRSKI N et al.: Prevalence of TNF-alpha blocker immunogenicity in psoriatic arthritis. J Rheumatol 2015; 42: 73-8.
19. PATEL DD, LEE DM, KOLBINGER F et al.: Effect of IL-17A blockade with secukinumab in autoimmune diseases. Ann Rheum Dis 2013; 72 (Suppl. 2): ii116-23.
20. FRLETA M, SIEBERT S, McINNES IB: The interleukin-17 pathway in psoriasis and psoriatic arthritis: disease pathogenesis and possibilities of treatment. Curr Rheumatol Rep 2014; 16: 414.
21. NESTLE FO, KAPLAN DH, BARKER J: Psoriasis. N Engl J Med 2009; 361: 496-509.
22. RAYCHAUDHURI SP: Role of IL-17 in psoriasis and psoriatic arthritis. Clin Rev Allergy Immunol 2013; 44: 183-93.
23. JANDUS C, BIOLEY G, RIVALS JP et al.: Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides. Arthritis Rheum 2008; 58: 2307-17.
24. SUZUKI E, MELLINS ED, GERSHWIN ME et al.: The IL-23/IL-17 axis in psoriatic arthritis. Autoimmun Rev 2014; 13: 496-502.
25. TAUSEND W, DOWNING C, TYRING S: Systematic review of interleukin-12, interleukin-17, and interleukin-23 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumab. J Cutan Med Surg 2014; 18: 156-69.
26. LEONARDI CL, GORDON KB: New and emerging therapies in psoriasis. Semin Cutan Med Surg 2014; 33 (Suppl. 2): S37-41.
27. MEASE PJ: Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis. Curr Opin Rheumatol 2015; 27: 127-33.
28. MEASE P, GENOVESE MC, GLADSTEIN G et al.: Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum 2011; 63: 939-48.
29. FONSECA JE, SANTOS MJ, CANHAO H et al.: Interleukin-6 as a key player in systemic inflammation and joint destruction. Autoimmun Rev 2009; 8: 538-42.
30. COSTA L, CASO F, CANTARINI L et al.: Efficacy of tocilizumab in a patient with refractory psoriatic arthritis. Clin Rheumatol 2014; 33: 1355-7.
31. MEASE P, STRAND V, SHALAMBERIDZE L et al.: A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate. Ann Rheum Dis 2012; 71: 1183-9.
32. MEASE PJ, GOTTLIEB A, BERMAN A et al.: A phase IIb, randomized, double-blind, placebo-controlled, dose-ranging, multicenter study to evaluate the efficacy and safety of clazakizumab, an anti-IL-6 monoclonal antibody, in adults with active psoriatic arthritis. Arthritis Rheum 2014; 66 (S10, abstract 952).
33. CELIS R, PLANELL N, FERNANDEZ-SUEIRO JL et al.: Synovial cytokine expression in psoriatic arthritis and associations with lymphoid neogenesis and clinical features. Arthritis Res Ther 2012; 14: R93.
34. MEASE PJ: Is there a role for rituximab in the treatment of spondyloarthritis and psoriatic arthritis? J Rheumatol 2012; 39: 2235-7.
35. MEASE P, KAVANAUGH A, GENOVESE M et al.: Rituximab in psoriatic arthritis provides modest clinical improvement and reduces expression of inflammatory biomarkers in skin lesions. Arthritis Rheum 2010; 62 (10 Suppl.): S818.
36. CUNNANE G, MADIGAN A, MURPHY E et al.: The effects of treatment with interleukin-1 receptor antagonist on the inflamed synovial membrane in rheumatoid arthritis. Rheumatology (Oxford) 2001; 40: 62-9.